Patents by Inventor Mark E. Curran

Mark E. Curran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6972176
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: December 6, 2005
    Assignees: University of Utah Research Foundation, Genzyme Corporation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski, Qing Wang
  • Publication number: 20030170708
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Application
    Filed: February 20, 2003
    Publication date: September 11, 2003
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski
  • Patent number: 6582913
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: June 24, 2003
    Assignees: University of Utah Research Foundation, Genzyme, Inc.
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski
  • Patent number: 6451534
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: September 17, 2002
    Assignees: University of Utah Research Foundation, Genzyme Corporation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski
  • Patent number: 6420124
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: July 16, 2002
    Assignees: University of Utah Research Foundation, Genzyme Corporation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski
  • Patent number: 6277978
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes are also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: August 17, 1998
    Date of Patent: August 21, 2001
    Assignees: University of Utah Research Foundation, Genzyme Corporation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski
  • Patent number: 5599673
    Abstract: The invention relates to the identification of the molecular basis of long QT syndrome. More specifically, the invention has identified that SCN5A and HERG cause long QT syndrome. Molecular variants of the SCN5A and HERG genes contribute to the syndrome. The analysis of these genes will provide an early diagnosis of subjects with long QT syndrome. The diagnostic methods comprise analyzing the nucleic acid sequences of the SCN5A or HERG genes of an individual to be tested and comparing them with the nucleic acid sequence of the native, nonvariant genes. Alternatively, the amino acid sequences of SCN5A or HERG may be analyzed for mutations which cause long QT syndrome. Presymptomatic diagnosis of long QT syndrome will enable practitioners to treat this disorder using existing medical therapy.
    Type: Grant
    Filed: March 9, 1995
    Date of Patent: February 4, 1997
    Assignee: University of Utah Research Foundation
    Inventors: Mark T. Keating, Mark E. Curran, Qing Wang
  • Patent number: 5166509
    Abstract: An optical modulator or laser source has a detector for detecting its output signal and for producing a corresponding output signal. A tapping device is connected to tap off a portion of the input modulation signal as a reference signal. The reference signal is compared and subtracted from the detector output signal by a subtraction unit in order to produce an error output signal which will be proportional to the laser noise/distortion components. This error signal is amplified and connected to an external modulator linked to the laser optical output and intensity modulates the laser output signal by the error signal in order to reduce or cancel the noise and distortion components in the signal.
    Type: Grant
    Filed: November 9, 1990
    Date of Patent: November 24, 1992
    Assignee: Tacan Corporation
    Inventor: Mark E. Curran
  • Patent number: 5113244
    Abstract: The fiber optic combiner/splitter is a positive and negative axicon combination which can convert a ring-shaped beam into a solid beam. The positive half of the axicon is effectively a plano-convex lens where the convex surface is generally a shallow cone. The flat surface of the lens abuts each end of an array of single mode fibers which are arranged in a ring configuration around a support member. The negative half of the axicon is effectively a plano-concave lens which is complementary to the positive lens. The focused beams from the positive half of the axicon are combined to form a single beam which is then directed into a single optical fiber. For conversions in the reverse direction, light is taken from a single multimode fiber and expanded into a ring-like pattern. The ring of light is picked up by the ring of single mode fibers. Each single mode fiber receives an equal amount of optical energy or power to provide good efficiency in splitting of the multiplexed beam.
    Type: Grant
    Filed: February 6, 1991
    Date of Patent: May 12, 1992
    Assignee: General Dynamics Corporation, Electronics Division
    Inventor: Mark E. Curran
  • Patent number: 5054875
    Abstract: A multi-mode optical fiber segment having partially reflecting mirrors on each end functions as a resonant cavity with respect to the modulation frequency when the length of the fiber is equal to one-half the modulation wavelength of the light injected into the fiber. Modulated light is injected through a hole in the mirror at one end, either from a fiber, a waveguide, or directly from a laser diode. The core diameter of the cavity fiber is limited only by the requirement that it must be much larger than the input hole. Light exits though a hole in the mirror opposite the input hole. Upon entry into the resonant cavity, light is subject to multi-modal propagation resulting in dispersion. The resultant output light of the fiber is lower overall in intensity, but its useful frequency response is expanded by the bandpass half-skirt of the fiber-optic filter.
    Type: Grant
    Filed: August 1, 1990
    Date of Patent: October 8, 1991
    Assignee: General Dynamics
    Inventor: Mark E. Curran